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OBJECTIVES We sought to test the hypothesis that vascular endothelial function is impaired in Behc¸et’s
syndrome and reflects increased levels of oxidative stress.
BACKGROUND Behc¸et’s syndrome is a multisystem inflammatory disorder commonly complicated by vascular
thrombosis and arterial aneurysm formation. The precise mechanisms underlying vascular
disease in Behc¸et’s syndrome are not known.
METHODS We studied 19 patients with Behc¸et’s syndrome (18 to 50 years old, 9 men) and 21 healthy
volunteers (18 to 50 years old, 10 men). Brachial artery flow-mediated dilation (endothelium-
dependent), and nitroglycerin (NTG)-induced dilation (endothelium-independent) were
measured. To investigate oxidative stress mechanisms, vascular studies were repeated 1 h after
administration of vitamin C (1 g, intravenous) in 12 patients and 12 control subjects.
RESULTS Flow-mediated dilation was reduced in patients with Behc¸et’s syndrome as compared with
control subjects (0.7 6 0.9% vs. 5.7 6 0.9%, p 5 0.001). In contrast, there were no significant
differences in the brachial artery diameter (4.2 6 0.2 vs. 4.0 6 0.2 mm, p 5 0.47) or
NTG-induced dilation (19.7 6 1.9% vs. 19.7 6 1.2%, p 5 0.98). In regression analysis,
Behc¸et’s syndrome was associated with impaired flow-mediated dilation independent of age,
gender, brachial artery diameter, blood pressure, cholesterol and glucose. Vitamin C increased
flow-mediated dilation in Behc¸et’s syndrome (0.2 6 0.7% to 3.5 6 1.0%, p 5 0.002), but not
in control subjects (4.3 6 0.6% to 4.7 6 0.4%, p 5 0.51). In both groups, NTG-induced
dilation and brachial artery diameter were unchanged after vitamin C treatment.
CONCLUSIONS Vascular endothelial function is impaired in Behc¸et’s syndrome and can be rapidly improved
by vitamin C treatment. Our results support a role for oxidative stress in the pathophysiology
of Behc¸et’s syndrome and provide a rationale for therapeutic studies aimed at reducing
vascular complications in this disorder. (J Am Coll Cardiol 2001;37:517–20) © 2001 by the
American College of Cardiology
Behc¸et’s syndrome is a chronic, multisystem disorder char-
acterized by recurrent oral and genital ulceration, skin
lesions and uveitis (1). In addition, ;25% of patients
develop vascular complications, which may include superfi-
cial thrombophlebitis, deep vein and arterial thrombosis and
arterial aneurysm formation (2).
The etiologic mechanisms underlying vascular disease in
Behc¸et’s syndrome are not well understood. Histopatho-
logic studies have demonstrated that the predominant lesion
is vasculitis, affecting both the vessel wall and perivascular
tissues (1). Reports of elevated serum concentrations of von
Willebrand factor, plasminogen activator inhibitor-1 and
thrombomodulin suggest the presence of vascular endothe-
lial dysfunction in patients with Behc¸et’s, although these
abnormalities have not been consistently found (3,4). Evi-
dence from recent studies suggests that activated leukocytes
may contribute to vascular injury in Behc¸et’s syndrome
(5,6). Neutrophils from patients with Behc¸et’s syndrome
generate high levels of oxygen-derived free radicals (5,6) and
cause endothelial cell lysis in vitro (6). Concentrations of
circulating pro-oxidants and lipid peroxidation products are
elevated in patients with Behc¸et’s syndrome (7), although
the relation between oxidative stress mechanisms and vas-
cular injury in patients with Behc¸et’s syndrome has not been
elucidated.
The purpose of the present study was to test the hypoth-
eses: 1) that vascular endothelial function is impaired in
Behc¸et’s syndrome; and 2) that endothelial dysfunction in
Behc¸et’s syndrome is mediated by oxidative stress mecha-
nisms and can be ameliorated by vitamin C treatment.
METHODS
Subjects. We studied 19 patients with Behc¸et’s syndrome
(18 to 50 years old, 9 men) and 21 healthy volunteers (18 to
50 years old, 10 men). Patients were identified at the
Rheumatology Clinic at the Hammersmith Hospital; they
had satisfied the International Study Group’s criteria for
Behc¸et’s syndrome (Table 1) (8). All patients were consid-
ered to have active disease at the time of the study, on the
basis of the presence of at least two of the major symptoms
of Behc¸et’s syndrome. Thirteen patients were receiving
treatment (prednisolone [n 5 10], azathioprine [n 5 6] and
colchicine [n 5 4]). Healthy volunteers were recruited from
the hospital staff, and none were receiving drug treatment.
All subjects were nonsmokers, with no history of diabetes,
hypertension, hypercholesterolemia or atherosclerotic vas-
cular disease. The study was approved by the local Ethics
Committee, and all subjects gave informed, written consent.
Clinical history, including drug therapy, was recorded in
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all subjects. Blood pressure was measured using a mercury
sphygmomanometer, and height and weight were recorded.
The subjects were studied after an overnight fast, and blood
samples were collected for glucose, total cholesterol, high
density lipoprotein (HDL) cholesterol and triglyceride lev-
els (Olympus AU800 multichannel analyzer).
For each subject, brachial artery flow-mediated dilation
(endothelium-dependent) and nitroglycerin (NTG)-induced
dilation (endothelium-independent) were measured, as de-
scribed subsequently. To investigate the role of oxidative stress
mechanisms in the observed vascular responses, brachial artery
measurements were repeated 1 h after administration of vita-
min C (1 g in 100 ml of normal saline, intravenously over
30 min) in 12 patients and 12 control subjects.
Brachial artery vascular measurements. Brachial artery
flow-mediated dilation was measured using a 7.0-MHz
linear array transducer, an Acuson 128XP/10 system
(Mountain View, California) and a high resolution ultra-
sonic vessel wall tracking system (Vadirec, Ingenious
Systems, Netherlands). In brief, the brachial artery was
scanned longitudinally, and the brachial artery diameter
was measured using the wall tracking system. After the
baseline rest scan, a pneumatic cuff placed at the level of
the wrist was inflated to 300 mm Hg for 4.5 min. The
second scan was performed 55 to 65 s after cuff deflation.
Fifteen minutes were allowed for vessel recovery, after
which the second baseline scan was performed. Nitro-
glycerin (400 mg) was then administered, and the fourth
scan of the brachial artery was taken. The vessel diameter
was measured by two independent observers who were
unaware of the subjects’ clinical details and the type and
stage of the study. The technique for measurement of
brachial artery flow-mediated dilation is reproducible in
our laboratory. The coefficient of variation for flow-mediated
dilation is 2%, based on measurements taken from the same
subjects, on separate days, under rest conditions. Flow-
mediated dilation of the conduit arteries is endothelium-
dependent and largely mediated by nitric oxide (9).
Data processing and statistical analysis. Data were ana-
lyzed using the Statistical Package for the Social Sci-
ences, version 8.0. Continuous data are expressed as the
mean value 6 SEM. The independent samples t test was
used to compare the mean values of flow-mediated
dilation, as well as other variables, between the two study
groups. Linear regression analyses were conducted to
investigate the association of Behc¸et’s syndrome with
flow-mediated dilation, independent of possible con-
founding effects. The effect of vitamin C on flow-
mediated dilation, NTG-induced dilation and brachial
artery diameter was studied in patients and control
subjects separately, using the paired samples t test.
Statistical significance was inferred at p , 0.05.
RESULTS
Clinical and biochemical characteristics. Compared with
control subjects, patients with Behc¸et’s syndrome were
similar in terms of age (40 6 2 vs. 41 6 2 years, p 5 0.70),
Abbreviations and Acronyms
HDL 5 high density lipoprotein
NTG 5 nitroglycerin
Table 1. Clinical Characteristics of Patients With Behc¸et’s Syndrome
Patient
Number
International Study Group Criteria for Behc¸et’s Syndrome*
Vascular
Complications
Oral
Ulcers
Genital
Ulcers
Skin
Lesions
Pathergy
Test
Ocular
Lesions
1 1 1 1
2 1 1 1
3 1 1 1
4 1 1 1
5 1 1 1 1
6 1 1 1 DVT
7 1 1 1 1 TIA
8 1 1 1 1
9 1 1 1
10 1 1 1
11 1 1 1
12 1 1 1
12 1 1 1
13 1 1 1 DVT
14 1 1 1
15 1 1 1 1
16 1 1 1
17 1 1 1
18 1 1 1 1
19 1 1 1 DVT
*See reference 8.
DVT 5 deep vein thrombosis; TIA 5 transient ischemic attack; 1 5 positive.
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body mass index (25 6 1.4 vs. 25 6 1.0 kg/m2, p 5 0.81),
diastolic blood pressure (71 6 2 vs. 71 6 2 mm Hg, p 5
0.78), fasting glucose (5.3 6 0.2 vs. 4.8 6 0.1 mmol/liter,
p 5 0.06), total cholesterol (5.2 6 0.2 vs. 4.8 6 0.1
mmol/liter, p 5 0.76) and HDL cholesterol (1.5 6 0.1 vs.
1.5 6 0.1 mmol/liter, p 5 0.80). Systolic blood pressure was
higher in patients than in control subjects (123 6 3 vs.
112 6 3 mm Hg, p 5 0.02).
Brachial artery flow-mediated dilation. Flow-mediated,
endothelium-dependent dilation was reduced in patients
with Behc¸et’s syndrome as compared with control subjects
(0.7 6 0.9 vs. 5.7 6 0.9%, respectively, p 5 0.001) (Fig. 1).
In contrast, there were no significant differences in baseline
brachial artery diameter (4.2 6 0.2 vs. 4.0 6 0.2 mm, p 5
0.47) or in brachial artery dilation in response to sublingual
NTG (19.7 6 1.9 vs. 19.7 6 1.2%, p 5 0.98) between
patients with Behc¸et’s syndrome and control subjects. On
regression analysis, Behc¸et’s syndrome was associated with
impaired flow-mediated dilation (partial regression coeffi-
cient 24.9 6 1.9%, p 5 0.01), independent of age, gender,
blood pressure, total and HDL cholesterol, triglycerides,
glucose and baseline brachial artery diameter.
Effects of vitamin C on vascular responses. In patients
with Behc¸et’s syndrome (n 5 12), administration of vitamin
C was associated with an increase in flow-mediated dilation
at 1 h (0.2 6 0.7 to 3.5 6 1.0%, p 5 0.002) (Fig. 2). In
contrast, NTG-induced dilation and baseline brachial artery
diameter were unchanged after vitamin C treatment (16.9 6
Figure 1. Flow-mediated dilation and NTG-induced dilation (mean value 6 SEM) in patients with Behc¸et’s syndrome (n 5 19) and control subjects (n 5
21).
Figure 2. Flow-mediated dilation (mean value 6 SEM) in patients with Behc¸et’s syndrome (n 5 12) and control subjects (n 5 12) before and 1 h after
intravenous vitamin C administration.
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1.9 vs. 14.8 6 1.3%, p 5 0.26; 4.1 6 0.2 vs. 4.2 6 0.3 mm,
p 5 0.99). In control subjects, administration of vitamin C
had no significant effect on flow-mediated dilation (4.3 6
0.6 to 4.7 6 0.4%, p 5 0.51) (Fig. 2), NTG-induced
dilation (18.6 6 1.1 vs. 21.0 6 2.2%, p 5 0.41) or brachial
artery diameter (4.0 6 0.2 vs. 4.0 6 0.2 mm, p 5 0.66).
DISCUSSION
We have found that vascular endothelial function is im-
paired in patients with Behc¸et’s syndrome and can be rapidly
improved by treatment with the antioxidant vitamin C. Our
findings of endothelial dysfunction—mediated by increased
oxidative stress—provide novel insight into the mechanisms
underlying the vascular manifestations of Behc¸et’s syndrome.
Endothelial function is impaired in Behc¸et’s syndrome.
Previous studies investigating endothelial function in pa-
tients with Behc¸et’s syndrome have not been consistent,
although they used indirect markers of vascular injury (3,4).
In the present study, we found that brachial artery flow-
mediated dilation is impaired in patients with Behc¸et’s
syndrome, as compared with healthy control subjects. Be-
cause flow-mediated dilation is endothelium-dependent and
mediated largely by the release of endothelial nitric oxide
(9), our findings imply that endothelial nitric oxide activity
is impaired in Behc¸et’s syndrome. Our observations are
consistent with previous reports of reduced plasma nitrates
and nitrites in patients with active Behc¸et’s syndrome (10)
and may help explain the vascular manifestations of this
disorder. Reduced activity of nitric oxide, the major
endothelium-derived vasodilator, may lead to vasoconstric-
tion, platelet aggregation and monocyte adhesion, which
separately or together may promote vascular disease in
patients with Behc¸et’s syndrome.
Mechanisms underlying endothelial dysfunction in
Behc¸et’s syndrome. The mechanisms underlying endo-
thelial dysfunction in Behc¸et’s syndrome are not known.
In the present study, vitamin C, an antioxidant that
scavenges superoxide anion radicals, rapidly increased
flow-mediated dilation in patients with Behc¸et’s syn-
drome. Our results suggest that endothelial dysfunction
is mediated by increased oxidative stress and are consis-
tent with previous observations of elevated levels of lipid
peroxides, as well as increased neutrophil production of
superoxide, in patients with Behc¸et’s syndrome (5,7).
Oxidative stress is a key factor in vascular injury. Previ-
ous studies have shown that oxygen-derived free radi-
cals, including superoxide anion, react with nitric oxide, thus
reducing its availability (11). However, our results do not
exclude an additional role for inflammatory cytokines, anti-
endothelial cell antibodies or vasoconstrictors, such as asym-
metric dimethyl arginine (12–14), underlying endothelial dys-
function in Behc¸et’s syndrome.
Clinical implications of our results. Currently there are
no reliable means to identify patients with Behc¸et’s
syndrome who have increased susceptibility to future
vascular complications. Measurement of brachial artery
flow-mediated dilation may provide a simple, reproducible and
noninvasive technique to identify patients at increased risk of
vascular disease. In addition, our observations—that vascular
endothelial function is impaired in Behc¸et’s syndrome, can be
improved by vitamin C treatment and may be mediated by
increased oxidative stress—provide a rationale for the use of
antioxidant vitamins to reduce vascular complications in this
disorder. However, because the short-term effects of vitamin C
treatment have not always been maintained (15), a long-term
intervention trial will be needed to formally evaluate this
possibility.
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